頁籤選單縮合
題 名 | SGLT2抑制劑治療第2型糖尿病=Strategy for Type 2 DM Treatment |
---|---|
作 者 | 黃馨瑩; 黃宗賢; 王慧瑜; 林双金; | 書刊名 | 藥學雜誌 |
卷 期 | 28:3=112 2012.09[民101.09] |
頁 次 | 頁56-60 |
分類號 | 418.271 |
關鍵詞 | 2型鈉-葡萄糖共同輸送器; Sodium-glucose co-transporter 2; SGLT2; Dapagliflozin; |
語 文 | 中文(Chinese) |
中文摘要 | 第2型糖尿病為多重病因的複雜性疾病,加上其逐年增加的盛行率、漸進式的疾病史及其相關的併發症,皆強調目前需要全新的治療策略。抑制鈉-葡萄糖共同輸送器 (sodium-glucose co-transporters, SGLTs),其中有一個關鍵作用為腎臟重吸收葡萄糖,已被發展作為一種新型糖尿病治療策略。目前第2型糖尿病治療常因副作用而導致其治療受到侷限。即使有多種口服藥品組合,或與胰島素合併治療,血糖控制仍很難維持。研究顯示,抑制2型鈉-葡萄糖共同輸送器,可以降低血糖及減少體重。雖然此類藥品正在進行的第三階段試驗的數據,需要更全面性地評估其安全性,但結果呈現,抑制2型鈉-葡萄糖共同輸送器和其它現行藥品相較,較無明顯副作用為其優勢。 |
英文摘要 | The increasing prevalence, variable pathogenesis, progressive natural history, and complications of type 2 diabetes emphasized the urgent need for new treatment strategies. Inhibiting sodium-glucose co-transporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. The use of current agents for T2DM is often limited by their potential to induce significant adverse effects. Glycaemic control can be difficult to attain, even with a combination of multiple oral agents, and with insulin added. These investigations indicate that elevating renal glucose excretion by suppressing SGLT2 can reduce plasma glucose levels, as well as decrease weight. Although data from ongoing Phase III trials of these agents are needed to more fully assess safety, results suggested that the beneficial effects of SGLT2 inhibition might be achieved without exerting significant side effects — an advantage over many current diabetes medications. |
本系統中英文摘要資訊取自各篇刊載內容。